
Opinion|Videos|June 26, 2024
Efficacy and Safety Trials Results of Complement Inhibitors
Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Several complement inhibitors have been approved since eculizumab, including ravulizumab, a long-acting C5 inhibitor; danicopan, a factor D inhibitor; pegcetacoplan, a complement C3 inhibitor; and iptacopan, a complement factor B inhibitor. Please discuss the efficacy and safety results from the pivotal trials for each of these treatments.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
2
Stronger Carer-Child Bonds Don’t Predict Later Mental Health
3
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
4
Intermountain Spans Time Zones, Cultures to Bring Oncology Care to Alaska
5















































